fda glp-1 warning letters september 2025 FDA takes aim at telehealth companies for promoting unofficial weight loss drug dupes

Today, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market. The agency will continue to

23.14

★★★★☆4.8 (126)

FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Compounding Pharmacy Operating Without Control

21.99

★★★★★4.9 (98)

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

24.30

★★★★★5.0 (157)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or

25.29

★★★★★4.7 (84)

September 8, 2025: FDA launches an import alert listing safe GLP-1 manufacturers – Partnership for Safe Medicines

22.60

★★★★★4.9 (203)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or quality and

29.04

★★★★★5.0 (176)

FDA Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded GLP-1 Marketing

21.33

★★★★★4.8 (132)